NASDAQ · CINC
CinCor Pharma, Inc.
$29.06$0.00 (0.0%)
CinCor Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.65% below the high.
Loading market information…
NASDAQ · PNT · USD
Stock price, earnings
Quote as of Dec 26, 2023, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
POINT Biopharma Global Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow POINT Biopharma Global Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
POINT Biopharma Global Inc. functions as a radiopharmaceutical company dedicated to the advancement and commercialization of specialized radioligand therapies designed to combat various cancerous conditions. Its two primary investigational treatments, both currently in Phase III clinical trials, are PNT2002, a radioligand engineered to target prostate-specific membrane antigen (PSMA) for addressing metastatic castration-resistant prostate cancer, and PNT2003, a somatostatin-targeted radioligand being evaluated for the treatment of neuroendocrine tumors. Beyond these late-stage programs, the company's pipeline includes earlier-stage product candidates such as PNT2001, a next-generation PSMA-targeting agent undergoing preclinical studies for non-metastatic castration-sensitive prostate cancer, and PNT-2004, a program focused on fibroblast activation protein-alpha (FAP-a) with broad potential across multiple tumor types, also in preclinical development. Additionally, POINT Biopharma is actively developing further drug candidates utilizing its CanSEEK technology, which it has sub-licensed from Bach Biosciences LLC and Avacta Life Sciences Limited. The company was established in 2019 and is headquartered in Indianapolis, Indiana.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2022 | May 13, 2022 | -$0.18+10.0% vs estimate | $0.00 |
|---|
| Q4 2021 | Mar 25, 2022 | -$0.16+20.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$29.06$0.00 (0.0%)
CinCor Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.65% below the high.
$9.10+$0.01 (+0.06%)
CTI BioPharma Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$2.34-$0.05 (-2.09%)
EQRx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.74% below the high.
$16.87+$0.02 (+0.12%)
VectivBio Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.65% below the high.
$11.13+$0.03 (+0.27%)
Verve Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
$9.50$0.00 (0.0%)
Poseida Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.76% below the high.
$13.48-$0.59 (-4.19%)
Crescent Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.82% below the high.
$10.25+$0.01 (+0.05%)
Gracell Biotechnologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.77% below the high.
